Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit

• DOI: 10.1111/ane.13162
• Publication Date: 2019-09-09T13:32:29Z
• Authors: Beatriz G. Giráldez; Iñigo Garamendi‐Ruiz; Jorge Zurita; Alberto García; Rosa Querol; Dulce Campos; Clara Cabeza‐Alvarez; Pedro Serrano; Francisco Javier ...; Albert Molins; José M. Serratosa
• Keywords: Tolerability; Discontinuation; Somnolence; Subgroup analysis; Retention rate

To assess the effectiveness and tolerability of eslicarbazepine acetate (ESL) monotherapy in routine clinical practice for treatment focal-onset seizures.Multicenter, retrospective, observational study conducted patients older than 16 years treated with ESL as first-line or converted to from polytherapy other monotherapy. Outcomes included 1-year retention rate, seizure-free rates after 6 12 months treatment, safety/tolerability issues.A total 256 were (106 150 conversion monotherapy; 56 aged >65 years). Overall, rate was 79% (72.7% ≥65 subgroup) at 59.3% 55.3% (72.2% 67.3% subgroup), without significant differences when comparing vs conversion-to-ESL groups (P = .979). However, group heterogeneous 43 (29.1%) that seizure free year prior introduction. A substantially higher proportion remained entire follow-up among those who initiated due problems compared inadequate control (71.4% 37.3%). 62 (24.2%) reported AEs (39.3% led discontinuation 20/256 (7.8%) (12.5% subgroup). Commonly somnolence (6.6%), dizziness (6.3%), headache (4.3%). Hyponatremia recorded five patients, majority (4/5) whom 65 years.Eslicarbazepine effective well-tolerated a setting adult elderly seizures.